As of November 6, 2026, Soleno Therapeutics Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 18, 2026 (Form 8-K, May 18, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Soleno Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Soleno Therapeutics Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-18. Every row below is cited to the filing it comes from, and this page adds each new change as Soleno Therapeutics Inc files it.
Also on the record for Soleno Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | — | 5%+ stakes | Source |
| May 18, 2026 | Acquired by Neurocrine Biosciences, Inc. | — | Acquisition | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 4.45% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Associates, Inc. | 2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 8.6% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.2% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 0.4% of the class | 5%+ stakes | Source |
| May 7, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 2.3% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.2% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 6.9% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by Avoro Capital Advisors LLC | 5.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Soleno Therapeutics Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Soleno Therapeutics Inc and the records around it.
Soleno Therapeutics Inc elsewhere on the record
- 5%+ stake filings Aug 2026
- Acquisition May 2026
- Who owns it
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026)
- Vivo Opportunity Fund Holdings, L.P. also filed stake reports on 20 other companies: ArriVent BioPharma, Inc. (Oct 2026), Clene Inc. (Aug 2026), Compass Therapeutics, Inc. (Aug 2026)
- Nantahala Capital Management, LLC also filed stake reports on 70 other companies: Research Alliance Corp III (Oct 2026), ADC Therapeutics SA (Aug 2026), Anteris Technologies Global Corp. (Aug 2026)
Watch Soleno Therapeutics Inc
Get an email when Soleno Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Soleno Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Soleno Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Soleno Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 27 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-18 | Reported | not named in the filing | 8-K, 2026-05-18 |
New leaders reset buying decisions — get the Full Report on Soleno Therapeutics Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Soleno Therapeutics Inc, with the record behind each one.
Find candidates like senior executive at Soleno Therapeutics IncEvery change, in the filing's words
Reported
Departure of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers The information set forth in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.
- In accordance with the terms of the Merger Agreement, each of Anish Bhatnagar, M.D., Mark Hahn, Matthew Pauls, Birgitte Volck, Andrew Sinclair and Dawn Bir resigned from his or her respective positions as a member of the Company's board of directors and all committees thereof effective as of the Effective Time.
- Immediately following the Effective Time, Matthew C. Abernethy and Darin M. Lippoldt became the directors of the Company, in each case, as of the Effective Time.
- The director resignations were tendered in connection with the Merger and were not a result of any disagreement between the Company and the directors on any matter relating to the Company's operations, policies or practices.
- In accordance with the terms of the Merger Agreement, (i) each of Anish Bhatnagar, M.D. (Chief Executive Officer), Jennifer Fulk (Chief Financial Officer), Patricia Hirano (Senior Vice President, Regulatory Affairs), Kristen Yen (Senior Vice President, Global Clinical Operations & Patient Advocacy), Meredith Manning (Chief Commercial Officer), Manher (AJ) Joshi (Chief Development Officer), Kevin Norrett (Chief Business Officer) and Michael Huang (Senior Vice President, Clinical Development) resigned from his or her positions as an officer of the Company, in each case, effective as of the Effective Time.
Tools for this story
Each opens in a new tab, filled in for Soleno Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.